Kornimate/medical-research-clean huggingface dataset:
senior pami: primary angioplasty versus thrombolytic therapy for acute myocardial infarction in the elderly

Conditions: Myocardial Infarction

Summary: this is a prospective, randomized, multi-center, international trial comparing two reperfusion strategies in elderly (age \>= 70 years) patients with acute myocardial infarction: primary percutaneous coronary intervention (pci) versus intravenous thrombolytic therapy. clinical endpoints will be collected in the hospital, at 1 month, 6 months, and 1 year post-randomization. the primary endpoint is 30 day death or disabling stroke. the study null hypothesis is that there will be no significant difference in death or disabling stroke at 30 days post-randomization between patients treated with pci versus thrombolytics.


Eligibility criteria:
inclusion criteria: * age \>= 70 * clinical symptoms \> 30 minutes * symptom onset \<= 12 hours * st segment elevation \>= 1 mm in 2 or more leads exclusion criteria: * prior thrombolytics * cardiogenic shock * cerebrovascular accident (cva) * prolonged cardiopulmonary resuscitation (cpr) * blood pressure (bp) \> 180/100 mm hg * active bleeding * international normalized ratio (inr) \> 1.4 * acetylsalicylic acid \[aspirin\] (asa) or heparin allergy * history of neutropenia, thrombocytopenia, hepatic dysfunction, or renal insufficiency * peripheral vascular disease (pvd)

Keywords: ami mi acute myocardial infarction (ami), (mi)
real-world patient reported outcomes among patients treated with camzyos

Conditions: Obstructive Hypertrophic Cardiomyopathy

Summary: this real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.


Eligibility criteria:
inclusion criteria: * participants ≥18 years of age. * participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy * provided informed consent to participate in the study exclusion criteria: * previously or currently enrolled in clinical trials for any cardiac myosin inhibitors * treated for \>7 days with mavacamten by the day of completing the baseline survey * enrolled in any clinical trials at the time of or within the six-month period prior to the screening * had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening * had stroke or transient ischemic attack within the six-month period prior to the screening * had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe * had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening * scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay * hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening

Keywords: obstructive hypertrophic cardiomyopathy
metabolic profile and adipokine levels in young hyperandrogenemic females

Conditions: Hyperandrogenism; Obesity; Metabolic Disease; Metabolic Syndrome

Summary: assessement of basic metabolic profile and adipokine levels in young hyperandrogenemic females.


Eligibility criteria:
inclusion criteria: * hyperandrogenemia * informed consent to participate * female sex * age 18-40 years old exclusion criteria: * male sex * no consent given
in vivo egfr-ecd molecular imaging using [68ga]- labelling anti-egfr affibody molecule

Conditions: Molecular Imaging

Summary: the investigators developed \[68ga\]-labelling anti-egfr affibody molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting egfr-ecd expression status.

the goals of investigators are to evaluate the use of \[68ga\]-labelling anti-egfr affibody molecule as a novel pet/ct radiotracer to monitor egfr-ecd expression status and classify egfr-ecd benefit nsclc patients. the investigators want to evaluated the use of \[68ga\]-labelling anti-egfr affibody molecule in lung cancer imaging in adult nsclc patients with different egfr-ecd expression status of primary and metastatic cancers.

Eligibility criteria:
inclusion criteria: * advanced nsclc * 18 years or older * a life expectancy of at least 12 weeks * presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (ct) * written informed consent exclusion criteria: * claustrophobia * pregnancy * metal implants in the thorax
a pharmacokinetic study of trk-100stp in japanese patients with renal impairment

Conditions: Renal Impairment

Summary: the pk and safety profiles to be examined following a single oral administration of trk-100stp (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.


Eligibility criteria:
inclusion criteria: * the egfr 1 day before study drug administration are stipulated as follows. * subjects with normal renal function : ≥90 * patients with mild renal impairment : ≥60 to \<90 * patients with moderate renal impairment : ≥30 to \<60 * patients with severe renal impairment : ≥15 to \<30 exclusion criteria: * patients on dialysis * patients who have a history of undergoing renal transplantation * patients with diabetes mellitus

Keywords: trk-100stp pk beraprost sodium japanese males and females subjects with mild/moderate/severe patients renal impairment
artisan aphakia lens for the correction of aphakia (secondary) in adults

Conditions: Aphakia

Summary: this study will determine the safety and effectiveness of the artisan aphakia lens when used as a secondary implant to correct aphakia in adults.

not desired

Eligibility criteria:
inclusion criteria: * patients 22 years of age and over at baseline visit of either sex and of any race where the natural lens has been removed or will be removed and a posterior chamber iol is not indicated. * patient must agree to comply with the visit schedule and other requirements of the study exclusion criteria: * patients that are not able to meet the extensive postoperative evaluation requirements * mentally retarded patients * when the patient has no useful vision or vision potential in the fellow eye * history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.), corneal dystrophy, degeneration, opacities or abnormalities that may affect vision. * abnormality of the iris or ocular structure which would preclude fixation, such as aniridia, hemiiridectomy, severe iris atrophy, rubeosis iridis, or other compromising iris pathology * patients with uncontrolled glaucoma * high preoperative intraocular pressure, \>25 mmhg * chronic or recurrent uveitis or history of the same * preexisting macular pathology that may complicate the ability to assess the benefit or lack of benefit obtained by the lens * patients with a retinal detachment or a family history of retinal detachment * retinal disease that may limit the visual potential of the eye such as retinopathy of prematurity or stargardt's retinopathy optic nerve disease that may limit the visual potential of the eye * diabetes mellitus * pregnant, lactating, or plans to become pregnant during the course of this study

Keywords: aphakia secondary intraocular lens
autologous bone marrow concentration for avascular necrosis of femoral head

Conditions: Avascular Necrosis of Femur; Bone Marrow

Summary: this study aims to evaluate the effect of bone marrow concentration on avascular necrosis of femur head by comparing clinical and imaging outcomes between patients receiving core decompression surgery with intraoperative bone marrow concentration and those receiving core decompression surgery only.

avascular necrosis (avn) of femoral head is a progressive disease that predominantly affects younger patients. although the exact pathophysiology of avn has not yet to be elucidated, the disease is characterized by a vascular insult to the blood supply of the femoral head, which can lead to collapse of the femoral head and subsequent degenerative changes. mesenchymal stem cells (mscs) are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. as bone marrow concentration has high concentration of mesenchymal stem cells, several studies have applied the autologous bone marrow concentration in halting the progression of avn of femoral head. however, a higher level of evidence for its use on patients suffering from femoral head avascular necrosis has not been reported. this clinical trial will evaluate and compare the eligible patients who undertake core decompression surgery plus intraoperative bone marrow concentration with those who received core decompression surgery only. all patients will be followed for one year and clinical and imaging outcomes will be compared and analyzed.

Eligibility criteria:
inclusion criteria: * age between 30 and 60 years * with diagnosis of avascular necrosis of femoral head, stage i - stage iii exclusion criteria: * with diagnosis of avascular necrosis of femoral head, stage vi - stage vi * with prior history of hip surgery * with current or prior history of trauma or infection at hip * platelet count \< 50,000/µl * with current diagnosis of coagulopathy * with current or prior history of cancer * with current or prior history of hematological disease * pregnancy * patients who will not cooperate with one-year followup

Keywords: femur head necrosis mesenchymal stromal cells bone marrow
systemic inflammatory markers in b-cell neoplasm

Conditions: B-cell Neoplasm

Summary: this study was to evaluate the role of systemic inflammatory markers in predicting outcome for patients with b cell neoplasm

in malignant tumors, inflammation plays a crucial role in the development, invasion, and metastasis of malignant tumors. cancer is often described as a wound that does not heal, highlighting the significance of inflammation in cancer progression. many tumors are heavily infiltrated by immune cells, including macrophages, neutrophils, and lymphocytes. therefore, markers related to inflammation and the host immune response are pertinent as biological indicators of b-cell neoplasm progression. inflammation contributes significantly to the initiation and advancement of b-cell neoplasms by providing nutrients to tumor cells, promoting cell growth, and disrupting immune homeostasis. various composite indices based on circulating inflammatory cells have been developed as straightforward measures to assess systemic inflammation. elevated serum inflammatory markers reflect the body's response to malignant tumors. pro-inflammatory cytokines and inflammatory cells within the tumor microenvironment have been shown to promote tumor growth, induce dna damage, facilitate angiogenesis, suppress the immune system, and correlate with poor patient survival outcomes. targeting cytokine receptors or other components in inflammatory pathways involved in metastasis may offer therapeutic potential for malignant tumors. given the pivotal role of inflammation in cancer biology, identifying novel immune markers is essential for predicting the prognosis of patients with diffuse large b-cell lymphoma (dlbcl). patients

Eligibility criteria:
inclusion criteria: * individuals newly diagnosed with b-cell neoplasms, including: * burkitt's lymphoma (bl) * chronic lymphocytic leukemia (cll) * diffuse large b-cell lymphoma (dlbcl) * follicular lymphoma (fl) * hairy cell leukemia (hcl) * splenic b-cell lymphoma/leukemia with prominent nucleoli (sblpn) * high-grade b-cell lymphoma (hgbl) * lymphoplasmacytic lymphoma (lpl)/waldenström macroglobulinemia * mantle cell lymphoma (mcl) * splenic marginal zone lymphoma (mzl) * monoclonal b-cell lymphocytosis (mbl) * multiple myeloma (plasma cell myeloma) * monoclonal gammopathy of undetermined significance (mgus) * age 18 years or older. exclusion criteria: * individuals previously diagnosed with b-cell neoplasms. * individuals younger than 18 years.

Keywords: systemic inflammatory markers as a prognostic index
postoperative peripheral nerve stimulation for management of post-amputation pain

Conditions: Phantom Limb Pain; Postoperative Pain; Neuroma; Acute Pain; Chronic Pain; Residual Limbs; Amputation

Summary: limb loss is frequently associated with postamputation pain that can be challenging to treat and often involves opioids. advances in the field of neuromodulation has led to development of an intentionally reversible percutaneous peripheral nerve stimulation (pns) system that has had promising results when treating chronic postamputation pain. pns may offer sustained pain relief even after the treatment period has ended. currently, there is no convincing evidence regarding the role of pns in the acute postoperative period, which may be a critical time to control pain as those with higher pain appear to be at higher risk for developing persistent post-procedural pain. the investigators of this study aim to evaluate the feasibility and effects of pns in the acute postoperative period and determine the feasibility of completing a randomized controlled treatment outcome study.

16 patients with new nontraumatic transfemoral or transtibial amputation will be enrolled in the study having met inclusion criteria, the patients will be randomized to experimental or control groups patients in the experimental group undergo placement of pns leads within 7 days of amputation surgery patients in both groups will be treated with standard pharmacologic and nonpharmacologic pain therapies and evaluated weekly for 8 weeks, then at 3, 6, and 12 months postamputation

Eligibility criteria:
inclusion criteria: * nontraumatic transfemoral (above-the-knee) or transtibial (below-the-knee) amputation * presence of postamputation pain rated at least 4 or more exclusion criteria: * beck depression inventory score greater than 20 * systemic infection * immunocompromised or taking immunosuppressive medications * implanted electronic device * pregnancy * previous allergy to skin contact materials and/or anesthetic agent * altered mental status * inability to provide informed consent

Keywords: neurostimulation peripheral nerve stimulation
correlation between brain structure and activity and spontaneous recovery of motor function following brain ischemic stroke

Conditions: Ischemic Stroke

Summary: the investigator aims to find a correlation between brain structure and activity and spontaneous recovery of motor function following brain ischemic stroke by analysis of mri scans. the research includes stroke patients and healthy patients (control group).

the recovery process, especially the recovery of motor functions after an ischemic stroke, differs from one person to another. in recent years, there is more evidence of spontaneous biological recovery (sbr), which is independent of training or rehabilitation-induced recovery, throughout the post-stroke subacute phase. however, the neural basis associated with motor function in this recovery phase remains unknown. we believe that the research results may help to explain the neural mechanism which promotes or inhibits recovery.

Eligibility criteria:
inclusion criteria: 1. age between 21 years old and 80 years old 2. admission to the hospital 2-14 days after a first ischemic stroke, confirmed by ct, mri or neurological report 3. residual unilateral upper extremity weakness 4. ability to give informed consent and understand the tasks involved. exclusion criteria: 1. younger than 21 years old or older than 80 years old 2. cognitive impairment, as seen by a score of \<20/30 on the montreal cognitive assessment (moca) 3. history of a physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, parkinson's disease) 4. contraindication to transcranial magnetic stimulation (tms), such as deep brain stimulators or skull defect, presence of other metal devices or objects in the head, or a pacemaker 5. inability to sit in a chair and perform upper limb exercises for one hour at a time 6. inability to lie down in the mri scanner for an hour 7. participation in another upper extremity rehabilitative therapy study during the study period 8. terminal illness 9. social and/or personal circumstances that interfere with the ability to return for therapy sessions and follow-up assessments 10. pregnancy 11. severe visuospatial neglect, as seen by a score of \<44/54 on the star cancellation test.
pharmacokinetics and safety of shr0302 in patients with hepatic impairment

Conditions: Hepatic Impairment

Summary: study to evaluate pharmacokinetics and safety of shr0302 in patients with mild, moderate hepatic impairment and normal liver function in phase i clinical study


Eligibility criteria:
inclusion criteria: all subjects:： * signing the informed consent forms； * 18 years to 65 years (inclusive)； * body mass index should be between 18 and 30 kg/m2 (inclusive)； * no medication was used before screening，or stable medication for 4 weeks. normal liver function： * clinical laboratory tests during the screening period were normal，or the abnormality has no clinical significance. hepatic impaired subjects: * child-pugh classification score clinically determined as mild or moderate hepatic impairment. * liver damage due to primary liver disease. exclusion criteria: all subjects: * subject known or suspected of being sensitive to the study drugs or its ingredient； normal liver function： * previous history of liver function impairment, or physical examination and laboratory examination at screening indicated the presence or possibility of liver function impairment. * hepatitis b surface antigen (hbsag) positive or anti-hepatitis c virus (hcv) antibody or hepatitis c core antigen positive within 3 months prior to administration. hepatic impaired subjects: * suspected or diagnosed as liver cancer or with other malignant tumors; * drug induced liver injury，acute liver injury，liver transplantation history. * subjects with hepatic failure,or severe complications caused by hepatocirrhosis.
gastrointestinal motility in severe ulcerative colitis obtained by motilis-3d-transit

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to describe gastrointestinal (gi) motility in patients suffering from severe ulcerative colitis (uc) and to compare these results with similar results obtained in remission. the study is done with the use of motilis 3d-transit system which consists of a small electronic capsule ingested and detected by a receiver carried by the patient. position and orientation of the capsule are interpreted by dedicated computer software and transit times, progression velocity and contraction frequencies can be revealed. the study is mainly descriptive and is designed to test and evaluate the usefulness of the motilis 3d transit system in uc patients and to tell investigators more about gi motility during and after severe inflammation. motilis 3d-transit system gives investigators a unique chance to study the gastrointestinal canal as a whole during and after severe illness. the investigators expect to include 20 patients suffering from severe uc admitted to hospital with the purpose of getting medical treatment. the investigators do not expect any drop out, but in case of drop out a new patient will be included.


Eligibility criteria:
inclusion criteria: * severe ulcerative colitis (modified truelove and witt score) * signed informed consent obtained * fasted since midnight exclusion criteria: * known gi related symptoms complaints or gi diseases * swallowing disorders * cancer or other life threatening diseases or conditions * pregnancy or breast-feeding * previous abdominal surgery * abdominal diameter \>140cm? * drug abuse or alcoholism * irregular bowel movements * known cardiovascular or pulmonary diseases * participation in any clinical study within the last 30 days * cardiac pacemaker or infusion pump or any other implanted or portable electro-mechanical medical device. * medication affecting gi motility * mri within the next four weeks

Keywords: gastrointestinal motility inflammatory bowel disease transit time
anesthesia and postoperative outcome in colorectal cancer patients

Conditions: Colorectal Cancer

Summary: study aims to compare the influence of tiva and sevoflurane anesthesia with or without lidocaine on postoperative short and long term outcome in patients with colorectal cancer undergoing surgery. as short term endpoints postoperative pain and opioid consumption, resumption of bowel function, ponv, los will be registered. long term outcome parameters include: the incidence of chronic pain, 1 and 5 years cancer recurrences incidence and mortality.

main goals 1. comparative evaluation of the incidence of recurrences after tiva vs sevoflurane anesthesia 2. evaluation of the effect of lidocaine infusion associated with tiva/sevoflurane on the incidence of chronic pain and of cancer recurrences and survival. secondary objectives 1. evaluation of the influence of lidocaine on postoperative outcome in patients with colorectal cancer 2. evaluation of the influence of lidocaine on postoperative inflammatory response 3. evaluation of the influence of lidocaine on the incidence and severity of postoperative pain and outcome in patients with colorectal cancer

Eligibility criteria:
inclusion criteria: * elective surgery exclusion criteria: * • persistent chronic pain * chronic medication that may interfere with pain: antiepileptics, nsaid, corticoids * contraindications for any of the study medications * significant psychiatric disorders (axa i) (major depression, bipolar disorders, schizophrenia, etc.) * significant hepatic (alat and/or asat \> 2 normal values) or renal (plasma creatinine \> 2 mg/dl) disorders * convulsive disorders requiring medication during the last 2 years * planned regional analgesia/anesthesia (spinal or epidural) * corticoid dependent asthma * autoimmune disorders * anti-arrhythmic medication (verapamil, propafenone, amiodarone) that may interfere with lidocaine's anti-arrhythmic effects * refusal for study participation

Keywords: colorectal cancer tiva sevoflurane lidocaine
acupoint stimulation improves sleep on the plateau

Conditions: Sleep Disorder

Summary: sleep disorder is common in people going to plateau. acupuncture and related techniques could be used for treatment of sleep disorder. in this trial the effect of transcutaneous electrical acupoint stimulation on sleep disorder in people going to plateau will be investigated.


Eligibility criteria:
inclusion criteria: * age from 18 to 40 years * first time to the plateau (altitude ≥3000 meters) exclusion criteria: * those who live in area with altitude ≥2000 meters, or travel to plateau in the last half year * history of insomnia * patients with contraindication to transcutaneous electrical stimulation, including skin damage, infection or implantable electrical device * difficulty in verbal communication * history of taking medicine to improve sleep during the last 3 months * regular daily intake of large dose of tea or coffee (\>400 mg of caffeine) * suspected or existed abuse of drug or alcohol * disease that influence sleep such as chronic pain

Keywords: transcutaneous electrical acupoint stimulation plateau sleep disorder healthy volunteer